Eton Pharmaceuticals, Inc. ETON · Stock Open Eton Pharmaceuticals, Inc. in new tab
Eton Pharmaceuticals, Inc. Analysis (ETON)
Is Eton Pharmaceuticals, Inc. a good investment? Eton Pharmaceuticals, Inc. (ETON) is currently trading at 45.14 USD. Market analysts have a consensus price target of 54.75 USD. This suggests a potential upside from current levels.
Earnings Schedule: Eton Pharmaceuticals, Inc. is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is 2.18.
Investor FAQ
Does Eton Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Eton Pharmaceuticals, Inc.?
Eton Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -0.06.
Company Profile
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Community Discussion